The role of immunohistochemical adrenomedullin and Bcl-2 expression in development of type-1 endometrial adenocarcinoma: Adrenomedullin expression in endometrium

详细信息    查看全文

• 作者：Kemal K&uuml ; rşat Bozkurt^a ; ^{kemalkbozkurt@hotmail.com" class="auth_mail" title="E-mail the corresponding author} ; Yakup Yalç ; ın^b ; ^{dryakupyalcin@gmail.com" class="auth_mail" title="E-mail the corresponding author} ; Ebru Erdemoğlu^c ; ^{ebru.md@hotmail.com" class="auth_mail" title="E-mail the corresponding author} ; Burak Tatar^b ; ^{buraktatar@yahoo.com" class="auth_mail" title="E-mail the corresponding author} ; Evrim Erdemoğlu^b ; ^{evrimmd@yahoo.com" class="auth_mail" title="E-mail the corresponding author} ; Sevim S&uuml ; reyya Ç ; erç ; i^d ; ^{sureyyacerci@hotmail.com" class="auth_mail" title="E-mail the corresponding author} ; İbrahim Metin Ç ; iriş^a ; ^{metin@metinciris.com.tr" class="auth_mail" title="E-mail the corresponding author} ; Şirin Başpınar^a ; ^{sirinbaspinar@gmail.com" class="auth_mail" title="E-mail the corresponding author} ; Afife Uğuz^a ; ^{afifenalinci@hotmail.com" class="auth_mail" title="E-mail the corresponding author} ; Nilg&uuml ; n Kapucuoğlu^e ; ^{nilgunkap@hotmail.com" class="auth_mail" title="E-mail the corresponding author}
• 关键词：Adrenomedullin ; Bcl-2 ; Endometrium ; EIN ; Adenocarcinoma
• 刊名：Pathology - Research and Practice
• 出版年：2016
• 出版时间：May 2016
• 年：2016
• 卷：212
• 期：5
• 页码：450-455
• 全文大小：4903 K

文摘

Adrenomedullin (AM) is a pluripotent peptide first discovered from human pheochromocytoma. AM expression has been shown in various cancer types including endometrium cancer. Bcl-2 is an antiapoptotic protein which might be regulated by AM in hypoxic conditions. The aim of the present study was to investigate the role of AM and Bcl-2 expressions in carcinogenesis of type-1 endometrium cancer.

Materials and method

Study group consisted of 10 proliferative endometrium, 22 simple endometrial hyperplasia, 23 endometrial intraepithelial neoplasia (EIN) and 30 Grade 1 endometrioid adenocarcinoma patients. AM and Bcl-2 expressions were investigated by immunohistochemistry.

Results

Mean AM Allred score was 3 ± 2.6, 5.6 ± 1.6 and 5.7 ± 2.5 in benign, EIN and adenocarcinoma groups, respectively. AM expression was significantly higher in EIN and adenocarcinoma groups than in benign endometrium group (p < 0.05). Mean Bcl-2 Allred score was 6.4 ± 2.1, 5.2 ± 2.6, 2.3 ± 2 in benign endometrium, EIN and adenocarcinoma groups, respectively. Mean Bcl-2 Allred score was similar between benign endometrium and EIN groups (p > 0.05). However, it was significantly lower in adenocarcinoma group (p < 0.05). An inverse correlation between AM and Bcl-2 expressions was found (r: −0.4, p < 0.001).

Conclusions

Our findings showed that AM expression increased in progression from benign endometrium to EIN and type-1 adenocarcinoma while expression of Bcl-2 decreased in transition from EIN to carcinoma.